Intranasal glucocorticosteroids – Not only in allergic rhinitis In the 40th anniversary of intranasal glucocorticosteroids’ introduction

Publication date: March–April 2014 Source:Otolaryngologia Polska, Volume 68, Issue 2 Author(s): Bolesław Samoliński , Anna Nowicka , Oksana Wojas , Agnieszka Lipiec , Edyta Krzych-Fałta , Aneta Tomaszewska It has been 40 years since Niels Mygind's publication in British Medical Journal on intranasal application of beclomethasone dipropionate aerosol in allergic rhinitis (AR). Since then a new era in treatment of allergic and nonallergic upper airway diseases began. This publication presents current concepts on application of intranasal glucocorticosteroids (inGCS) in treatment of upper airway diseases and in particular of AR and rhinosinusitis. Nonquestionable advantage of inGCS is their strong anti-inflammatory local action with little impact on general health responsible for few and benign side effects. Main way of action of glucocorticosteroids is connected with binding to the intracellular glucocorticosteroid receptor and its impact on nuclear cytoplasmic transcriptional factors. Glucocorticosteroids suppress gene expression of factors responsible for generating and supporting inflammatory processes, proinflammatory cytokines and chemokines production, and adhesive molecules expression. It appears that glucocorticosteroids have also other mechanisms of action, non-involving intracellular receptors, leading to inhibition of early and late phase of allergic reaction. At the moment the following glucocorticosteroids are registered in Poland: beclomethasone, bu...
Source: Otolaryngologia Polska - Category: ENT & OMF Source Type: research